Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page

NIDA Home > Publications > Director's Reports > May, 2010 Index    

Director's Report to the National Advisory Council on Drug Abuse - May, 2010


NIDA Publications

Research Report Series: Marijuana (Revised) NIH Pub. No. 10-3859
This report contains current data based on an extensive review of scientific literature on the scope of marijuana abuse in the United States, as well as its physical and social effects. NIDA addresses the adverse physical, mental, emotional and behavioral changes associated with heavy marijuana use in this publication and presents an overview of study results on health consequences of marijuana abuse.

Drugs, Brains, and Behavior: The Science of Addiction (Rev.) NIH Pub. No. 10-5605
The "Science of Addiction" explains in layman's terms how science has revolutionized our understanding of drug addiction as a brain disease that affects behavior. It uses simple language, diagrams, and graphics to help people understand how drugs change the brain in structure and in function. The booklet explains some of the reasons that people take drugs, helps explain why some people become addicted while others do not, and demonstrates how addiction, like other chronic diseases, may be prevented and treated.

Research Report Series: Cocaine and Addiction (Sp.) NIH Pub. No. 10-4166
This updated version contains scientific information on crack and cocaine. Facts based on the latest technology are used to describe the different effects of this drug; as well as the pathways in the brain that it affects; the medical consequences of use; and some behavioral treatments for cocaine abuse. NIDA also reports on several pharmacological compounds currently being tested for their potential use in treating cocaine addiction.

Research Report Series: Tobacco Addiction (Sp.) NIH Pub. No. 18-4342
This updated version describes what tobacco is, presents current epidemiological research data regarding its use, and reports on the medical consequences of tobacco use. Emphasizes the effects on the brain as well as current research findings about use during pregnancy. It also includes treatment approaches.

Principles of Drug Addiction Treatment: A Research-Based Guide (Revised) (Sp.)
NIH Pub. No. 10-4180

This second edition of the "Blue Book" includes updated principles, new questions, new program information, and expanded references and resources based on the latest findings from NIDA-funded research. Thirteen fundamental principles of effective treatment for addiction are outlined that include defining the disease of addiction to recognizing that it often co-occurs with other health conditions—all of which need to be addressed for the patient to successfully recover. This publication is intended to help patients and their families learn more about what they can expect from drug abuse treatment and how to optimize their results and minimize their difficulties. It also serves as a resource for healthcare providers seeking information about the various drug abuse treatment options.


NIDA NOTES, Vol. 23, No. 1
The lead article in this issue describes how an activity called the Good Behavior Game, which is played in the primary grades, produces a spectrum of long-term benefits in young adults, including reductions in substance abuse, delinquency, and antisocial personality disorder. The issue also reports research findings indicating that youths who abuse opioids benefit from extended treatment with buprenorphine and naloxone. Another feature presents evidence that vouchers can increase the efficacy of smoking abstinence programs for pregnant women and improve fetal growth. The issue also includes a report that for people with both bipolar disorder and substance abuse problems, group counseling that addresses the two conditions is more effective than standard substance abuse group counseling. In the Director's Perspective, Dr. Nora Volkow introduces NIDAMED, the Institute's comprehensive physician-outreach initiative. The issue also reviews the activities of NIDA's Genetics Workgroup in the search for genes that influence addiction.


Issue #28 of NIDA in the News was distributed to all NIDA HQ, IRP and contractor staff on February 18, 2010.

CTN-Related Publications

Seven editions of the CTN Bulletin Board were distributed. The Bulletin Board is an electronic report on the progress of the protocols, committees, and node activity in the CTN. The Bulletin has wide readership within and outside the CTN and NIDA.

Data from 22 CTN trials are now available on the CTN Data Sharing Web Site. Over 300 research scientists have downloaded one or more data sets. These data sets are in compliance with HIPAA and CDISC (Clinical Data Interchange Standards Consortium) standards in support of the interoperability required by the NIH Roadmap.

International Program-Related Publications

NIDA IP's New Mission Brochure
A new, four-page color brochure highlights NIDA IP's pivotal work in promoting international collaborative drug abuse research, training, and exchange. The brochure briefly describes NIDA IP's efforts to link NIDA to the world through partnerships with countries, organizations, and individual researchers; support research through Program Announcements and Requests for Applications; build capacity through research training and professional development opportunities; and share knowledge through a variety of channels. The back of the brochure spotlights the annual NIDA International Forum and lists the NIDA IP Web site address. A downloadable PDF version of the brochure is available on the International Program's Web site at

NIDA IP Fellowships Flyer
NIDA IP has developed a new flyer to provide at-a-glance information on the variety of training fellowships and research exchanges that it offers for all levels of scientists interested in drug abuse research. Arranged by career level, the flyer's concise chart lists nine programs with key information on their respective eligible audiences, application deadlines, and what the fellowships include. A downloadable PDF version of the flyer is available on the International Program's Web site at

HHH Fellowship Flyer
The NIDA Humphrey Drug Abuse Research Fellowship is the focus of a new two-page flyer that promotes this unique component of the HHH Fellowship program. The brochure describes the focus of the fellowship, what it covers, who is eligible, and where and when to apply. In addition to listing resources for more information, the brochure gives an email address to request advice on preparing a competitive application. A downloadable PDF version of the flyer is available on the International Program's Web site at

IP E-News
March 2010 - This issue announced the availability of tuition waivers for the Dutch Summer Institute on Alcohol, Drugs and Addiction and training grants made available through the FIC as a result of U.S. economic stimulus funds. The issue also reported on an orientation program for new HHH fellows, the appointment of Dr. Phil Skolnick as the director of DPMCDA, three new INVEST-CTN fellows, new DISCA and USDISCA awardees, and the accomplishments of former INVEST and HHH fellows. This issue is available online at

Other Publications

Purohit V, Rapaka R, Shurtleff D. Role of cannabinoids in the development of fatty liver (Steatosis). AAPS Journal 2010; 12: 233-237. This publication is a part of the summary of the Cannabinoids and Liver Diseases Symposium organized by Vishnu Purohit and Rao Rapaka at the International Cannabinoid Research Symposium (ICRS) Meeting, St. Charles, Illinois, USA, July 8-11, 2009.

Chandler R, Dennis M, El-Bassel N, Schwartz R, Field, G. Ensuring safety, implementation, and scientific integrity of clinical trials: Lessons from the Criminal Justice-Drug Abuse Treatment Studies Data & Safety Monitoring Board. Journal of Experimental Criminology 2009; 5(3): 323-344.

Zanis DA, Coviello DM, Lloyd JJ, Nazar BL. Predictors of drug treatment completion among parole violators. Journal of Psychoactive Drugs 2009; 41(2): 173-180.

Khalsa J, Elkashef A. Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs. Am J Addict. 2010. Jan; 19(1): 96-100.

Schwandt ML, Lindell SG, Chen S, Higley JD, Suomi SJ, Heilig M, Barr CS. Alcohol response and consumption in adolescent rhesus macaques: life history and genetic influences. Alcohol. 2010 Feb; 44(1): 67-80.

Hiranita T, Soto PL, Tanda G, Katz JL. Reinforcing effects of σ-receptor agonists in rats trained to self-administer cocaine. Journal of Pharmacology and Experimental Therapeutics. 2010, 332: 515-524.

Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jorgensen TN, Holy M, Kudlacek O, Seidel S, Cha JH, Gether U, Newman AH, Ecker GF, Freissmuth M, Sitte HH. The amino terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem 2010; e-pub Jan 29.

Higley A, Spiller K, Grundt P, Newman AH, Kiefer S, Xi Z-X, Gardner EL. PG01037, a Novel Dopamine D3 Receptor Antagonist, Inhibits the Effects of Methamphetamine in Rats. J. Psychopharmacol. 2010; e-pub February 8.

Mason CW, Hassan HE, Kim KP, Cao J, Newman AH, Eddington ND, Voulalas PJ. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. J Pharmacol Exp Ther 2010; e-pub March 12, 2010.

Heidbreder CA, Newman AH. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders in Annals of the New York Academy of Science - Addiction Genetics, G. Uhl Ed.: 2010, 1187, 4-34. Invited review.

Shippenberg TS, Chefer VI, Thompson AC. Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine. Biol Psychiatry. 2009 Jan 15; 65(2):169-174.

Chefer VI, Shippenberg TS. Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsycho-pharmacology. 2009 Mar; 34(4):887-898. Epub 2008 Aug 13.

Oz M, Jaligam V, Galadari S, Petroianu G, Shuba YM, Shippenberg TS. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J Neurochem. 2009 Dec 24.

Yang KH, Galadari S, Isaev D, Petroianu G, Shippenberg TS, Oz M. The nonpsychoactive cannabinoid cannabidiol inhibits 5-HT3A receptor-mediated currents in xenopus oocytes. J Pharmacol Exp Ther. 2010 Feb 16.

Oz M, Jaligam V, Galadari S, Petroianu G, Shuba YM, Shippenberg TS. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J Neurochem. 2009 Dec 24.

Chefer VI, Denoroy L, Zapata A, Shippenberg TS. Mu opioid receptor modulation of somatodendritic dopamine overflow: GABAergic and glutamatergic mechanisms. Eur J Neurosci. 2009 Jul; 30(2): 272-278.


Research Findings

Program Activities

Extramural Policy and Review Activities

Congressional Affairs

International Activities

Meetings and Conferences

Media and Education Activities

Planned Meetings


Staff Highlights

Grantee Honors

Get Adobe Reader

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. The U.S. government's official web portal